Literature DB >> 9291165

Modulation of autoimmune responses by intravenous immunoglobulin (IVIg).

S Kaveri1, N Prasad, T Vassilev, V Hurez, A Pashov, S Lacroix-Desmazes, M Kazatchkine.   

Abstract

Significant progress has been made in understanding the mechanisms by which intravenous immunoglobulins (IVIg) exert immunomodulatory effects in the treatment of autoimmune diseases. A unique property of immunoglobulins is the diversity of variable (V) regions. The evidence discussed in this communication supports our notion that the diversity of V regions in IVIg preparations is a determining factor for the anti-inflammatory substitutive and immunomodulatory functions of IVIg therapy. We have demonstrated the presence in IVIg, of anti-idiotypic antibodies directed against various autoantibodies. The ability of IVIg to interact through V regions with complementary V regions of antibodies and antigen receptors as well as with relevant soluble and surface molecules provides the basis for inducing the selection of immune repertoires. The study of the mechanisms by which IVIg mediates selection of autoreactive repertoires is essential for our understanding of the mechanisms underlying the emergence of pathological autoimmunity and of the physiological role of natural antibodies in the establishment and maintenance of tolerance to self and homeostasis of autoreactivity in healthy individuals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291165     DOI: 10.1177/135245859700300211

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  4 in total

1.  From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies.

Authors:  S Y Patel; D S Kumararatne
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

2.  The Effect of Container Surface Passivation on Aggregation of Intravenous Immunoglobulin Induced by Mechanical Shock.

Authors:  Sanli Movafaghi; Hao Wu; Irene M Francino Urdániz; David S Bull; Mary D Kelly; Theodore W Randolph; Andrew P Goodwin
Journal:  Biotechnol J       Date:  2020-06-08       Impact factor: 4.677

3.  IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions.

Authors:  Signe Humle Jorgensen; Nicolas Storm; Poul Erik Hyldgaard Jensen; Henning Laursen; Per Soelberg Sorensen
Journal:  Exp Brain Res       Date:  2006-11-08       Impact factor: 1.972

4.  Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervicovaginal secretions.

Authors:  Jobin Eslahpazir; Mohammad-Ali Jenabian; Hicham Bouhlal; Hakim Hocini; Cédric Carbonneil; Gérard Grésenguet; François-Xavier Mbopi Kéou; Jérôme LeGoff; Héla Saïdi; Mary Requena; Nadine Nasreddine; Jean de Dieu Longo; Srinivas V Kaveri; Laurent Bélec
Journal:  Clin Vaccine Immunol       Date:  2008-03-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.